- Programs & Services
- Cost Management
- Specialty Management
- Care Management
- Member Engagement
- Health Plan Client Engagement
Brian Alexander, MD, MPH, CEO, Foundation Medicine
Next-Generation Sequencing (NGS) is woefully underused today. Reasons may include lack of payor coverage, lack of provider understanding and long delays in results. But the benefits of NGS are increasing. Dr. Alexander noted that 90 targeted therapies are now available across 25 cancer types and reviewed which tumors should be paired with NGS and how to avoid using gene tests whose results do not change the course of therapy.